ContraFect to Present at Piper Jaffray Health Care Conference
November 19 2018 - 7:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, today announced that Steven C. Gilman, Ph.D.,
the Company's Chairman and Chief Executive Officer, will
participate in a fireside chat at the Piper Jaffray Health Care
Conference on Wednesday, November 28, 2018 at 9:00 AM ET in New
York, NY. The focus will be on ContraFect's lead program, exebacase
(CF-301), the Company's potential novel treatment for
Staphylococcus aureus (Staph aureus) bacteremia, including
endocarditis, along with an update on the progress of its other
pipeline assets.
A live webcast of the presentation will be
available on the Investors & Media section of the Company’s
website at www.contrafect.com. The presentation will also be
available as an archived webcast for a limited time.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing therapeutic protein and antibody
products for life-threatening, drug-resistant infectious diseases,
particularly those treated in hospital settings. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses (regions that are
not prone to mutation). ContraFect's initial product candidates
include new agents to treat antibiotic-resistant infections such as
MRSA (Methicillin-resistant Staph aureus) and influenza.
ContraFect’s lead product candidate, exebacase (CF-301), is
currently in a Phase 2 clinical trial for the treatment of Staph
aureus bacteremia, including endocarditis and is the first lysin to
enter clinical studies in the U.S. ContraFect is also
conducting research focused on the discovery of lysins to target
Gram-negative bacteria.
About exebacase (CF-301):
Exebacase (CF-301) is a recombinant
bacteriophage-derived lysin with potent bactericidal activity
against Staph aureus, a major cause of blood stream infections, or
bacteremia. CF-301 has the potential to be a first-in-class
treatment for Staph aureus bacteremia. It has a novel, rapid,
and specific mechanism of bactericidal action against Staph aureus
and does not impact the body's natural bacterial flora. By
targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to CF-301.
Combinations of CF-301 with standard of care antibiotics
significantly increased bacterial killing and survival in animal
models of disease when compared to treatment with antibiotics or
CF-301 alone. In addition, in vitro and in vivo experiments have
shown that CF-301 is highly active against biofilm infections.
Exebacase (CF-301) was licensed from The Rockefeller University and
is being developed at ContraFect. It is the first lysin to enter
clinical studies in the U.S.
Forward-Looking Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, whether
exebacase (CF-301) has the potential to be a novel treatment for
Staph aureus bacteremia, including endocarditis, statements made on
the progress of other pipeline assets, our ability to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses, whether our
initial product candidates which include new agents can treat
antibiotic-resistant infections such as MRSA and influenza, our
ability to discover new lysins targeting Gram-negative bacteria,
whether exebacase (CF-301) has potent bactericidal activity against
Staph aureus or it has the potential to be a first in class
treatment for Staph aureus bacteremia, including endocarditis,
results of in vitro and in vivo experiments, and statements made
regarding the Piper conference and the fireside chat.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Kerry ConlinStern Investor RelationsTel: 212-362-1200Email:
kerry@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024